MedPath

rTMS for Apathy Clinical Trial

Not Applicable
Recruiting
Conditions
Alzheimer Disease
Apathy in Dementia
Dementia
Mild Behavioural Impairment
Mild Cognitive Impairment
Neurocognitive Disorders
Interventions
Registration Number
NCT05561205
Lead Sponsor
Sunnybrook Health Sciences Centre
Brief Summary

Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in neurocognitive disorders and mild behavioural impairment in individuals receiving methylphenidate and individuals not receiving medication for apathy.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
10
Inclusion Criteria
  • mild or major neurocognitive disorder OR mild behavioural impairment
  • Apathy for at least 4 weeks
  • Stable dose of medication (>4 weeks) that may affect cognition or behaviour
  • Care partner who spends at least 10 hours a week with the subject
Exclusion Criteria
  • Current major depressive episode
  • Agitation, delusions, hallucination
  • Medical contraindications to rTMS
  • Currently taking an amphetamine product
  • Central nervous system abnormalities, Tourette's syndrome, or motor tics
  • Current participation in another clinical trial

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
rTMS onlyrTMSrepetitive transcranial magnetic stimulation (rTMS) only
rTMS + methylphenidaterTMSrepetitive transcranial magnetic stimulation (rTMS) and methylphenidate
rTMS + methylphenidatemethylphenidaterepetitive transcranial magnetic stimulation (rTMS) and methylphenidate
Primary Outcome Measures
NameTimeMethod
Neuropsychiatric Inventory-apathy2 weeks

Measure of apathy on a scale from 0 to 12 with a higher score indicating greater apathy

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Sunnybrook Health Sciences Centre

🇨🇦

Toronto, Ontario, Canada

Sunnybrook Health Sciences Centre
🇨🇦Toronto, Ontario, Canada
Carla Zucchero-Sarracini
Contact
416-480-6100
memoryresearch@sunnybrook.ca
Krista L Lanctôt, PhD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.